JP6505692B2 - 心不全治療のためのジスルフィド環状ポリペプチド - Google Patents

心不全治療のためのジスルフィド環状ポリペプチド Download PDF

Info

Publication number
JP6505692B2
JP6505692B2 JP2016529806A JP2016529806A JP6505692B2 JP 6505692 B2 JP6505692 B2 JP 6505692B2 JP 2016529806 A JP2016529806 A JP 2016529806A JP 2016529806 A JP2016529806 A JP 2016529806A JP 6505692 B2 JP6505692 B2 JP 6505692B2
Authority
JP
Japan
Prior art keywords
polypeptide
side chain
peptide
ester
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016529806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531110A (ja
JP2016531110A5 (https=
Inventor
ゼクリ，フレデリック
グロッシェ，フィリップ
佳代 八十島
佳代 八十島
チャオ，ホンジュアン
ユアン，ジュン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016531110A publication Critical patent/JP2016531110A/ja
Publication of JP2016531110A5 publication Critical patent/JP2016531110A5/ja
Application granted granted Critical
Publication of JP6505692B2 publication Critical patent/JP6505692B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2016529806A 2013-07-25 2014-07-21 心不全治療のためのジスルフィド環状ポリペプチド Expired - Fee Related JP6505692B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361858290P 2013-07-25 2013-07-25
US61/858,290 2013-07-25
PCT/US2014/047375 WO2015013167A1 (en) 2013-07-25 2014-07-21 Disulfide cyclic polypeptides for the treatment of heart failure

Publications (3)

Publication Number Publication Date
JP2016531110A JP2016531110A (ja) 2016-10-06
JP2016531110A5 JP2016531110A5 (https=) 2017-08-31
JP6505692B2 true JP6505692B2 (ja) 2019-04-24

Family

ID=51352764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016529806A Expired - Fee Related JP6505692B2 (ja) 2013-07-25 2014-07-21 心不全治療のためのジスルフィド環状ポリペプチド

Country Status (5)

Country Link
US (1) US9683018B2 (https=)
EP (1) EP3024847A1 (https=)
JP (1) JP6505692B2 (https=)
CN (1) CN105612174A (https=)
WO (1) WO2015013167A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
UY35144A (es) * 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105612174A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的二硫化物环状多肽
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
WO2015013165A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
SG11201609706VA (en) 2014-06-23 2017-01-27 Novartis Ag Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3366693B1 (en) * 2015-10-23 2023-08-16 FUJIFILM Corporation Cyclic peptide, affinity chromatography support, labeled antibody, antibody-drug conjugate, and pharmaceutical preparation
WO2017069269A1 (ja) * 2015-10-23 2017-04-27 富士フイルム株式会社 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤
EP3205664A1 (en) * 2016-02-11 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of liraglutide using bal linker
WO2018013053A1 (en) * 2016-07-15 2018-01-18 Agency For Science, Technology And Research Methods of diagnosis and treatment of pre-eclampsia
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CA3097812A1 (en) * 2018-04-25 2019-10-31 Janssen Pharmaceutica Nv Thioether cyclic peptide amylin receptor modulators
WO2019229242A1 (en) 2018-05-31 2019-12-05 Novo Nordisk A/S Derivatives comprising an apelin analogue and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
CA2728763A1 (en) * 2008-06-20 2009-12-23 The Board Of Regents Of The University Of Texas System Crkl targeting peptides
WO2010053545A2 (en) * 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Apj receptor compounds
JP5753159B2 (ja) * 2009-05-05 2015-07-22 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化
SI3045183T1 (sl) * 2011-03-11 2018-11-30 Genzyme Corporation Pegiliran Apelin in njegove uporabe
CU23950B1 (es) * 2011-03-21 2013-10-29 Ct De Ingeniería Genética Y Biotecnología Péptidos cíclicos con actividad antineoplásica y antiangiogénica
KR20140039257A (ko) * 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도
US8921307B2 (en) * 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
ES2732574T3 (es) * 2012-11-30 2019-11-25 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
CN105612174A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的二硫化物环状多肽
WO2015013165A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure

Also Published As

Publication number Publication date
US9683018B2 (en) 2017-06-20
WO2015013167A1 (en) 2015-01-29
JP2016531110A (ja) 2016-10-06
EP3024847A1 (en) 2016-06-01
CN105612174A (zh) 2016-05-25
US20160145309A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
JP6505692B2 (ja) 心不全治療のためのジスルフィド環状ポリペプチド
JP6595553B2 (ja) 心不全治療用の合成アペリン模倣物
JP6501775B2 (ja) 心不全治療用の環状ポリペプチド
JP6505691B2 (ja) 心不全治療用の環状アペリン誘導体
JP6444882B2 (ja) 心不全治療用の合成鎖状アペリン模倣物
JP2016527249A (ja) 合成アペリンポリペプチドのバイオコンジュゲート
US20140155315A1 (en) Synthetic linear apelin mimetics for the treatment of heart failure
HK1200470B (en) Synthetic apelin mimetics for the treatment of heart failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190327

R150 Certificate of patent or registration of utility model

Ref document number: 6505692

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees